BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11328309)

  • 1. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience.
    Stussi G; Seebach L; Muntwyler J; Schanz U; Gmür J; Seebach JD
    Br J Haematol; 2001 Apr; 113(1):251-3. PubMed ID: 11328309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
    Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
    Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
    Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Bacigalupo A; Van Lint MT; Occhini D; Margiocco M; Ferrari G; Pittaluga PA; Frassoni F; Peralvo J; Lercari G; Carubia F
    Transplantation; 1988 Jun; 45(6):1091-4. PubMed ID: 3289150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
    N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.
    Benjamin RJ; McGurk S; Ralston MS; Churchill WH; Antin JH
    Transfusion; 1999 Feb; 39(2):179-87. PubMed ID: 10037129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?
    Gutiérrez-Aguirre CH; Gómez-De-León A; Alatorre-Ricardo J; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; Mancías-Guerra C; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2014 May; 54(5):1269-77. PubMed ID: 24898453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ABO-incompatible allogeneic bone marrow transplantation].
    Xu L; Guo N; Wang S
    Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):413-5. PubMed ID: 11721421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT).
    Schmitz N; Bacigalupo A; Labopin M; Majolino I; Laporte JP; Brinch L; Cook G; Deliliers GL; Lange A; Rozman C; Garcia-Conde J; Finke J; Domingo-Albos A; Gratwohl A
    Br J Haematol; 1996 Dec; 95(4):715-23. PubMed ID: 8982051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival.
    Xenocostas A; Yee A; Wong CJ; Sutton DM; Lipton JH; Kiss TL; Messner HA
    Transfusion; 2003 Mar; 43(3):373-82. PubMed ID: 12675724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation.
    Stockschläder M; Hassan HT; Krog C; Krüger W; Löliger C; Horstman M; Altnöder M; Clausen J; Grimm J; Kabisch H; Zander A
    Br J Haematol; 1997 Feb; 96(2):382-6. PubMed ID: 9029030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia: management of relapse after allogeneic bone marrow transplantation.
    Kumar L
    J Clin Oncol; 1994 Aug; 12(8):1710-7. PubMed ID: 8040682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
    Ringdén O; Labopin M; Gorin NC; Schmitz N; Schaefer UW; Prentice HG; Bergmann L; Jouet JP; Mandelli F; Blaise D; Fouillard L; Frassoni F;
    Br J Haematol; 2000 Dec; 111(4):1130-7. PubMed ID: 11167752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor.
    Balduini CL; Frassoni F; Noris P; Klersy C; Iannone AM; Bacigalupo A; Giorgiani G; Di Pumpo M; Locatelli F
    Br J Haematol; 2001 Sep; 114(4):951-3. PubMed ID: 11564091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.